GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ondine Biomedical Inc (OTCPK:OBIMF) » Definitions » Net Issuance of Preferred Stock

OBIMF (Ondine Biomedical) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Ondine Biomedical Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Ondine Biomedical's net issuance of preferred for the six months ended in Jun. 2024 was $0.00 Mil. The number is 0, which means that Ondine Biomedical has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Ondine Biomedical's net issuance of preferred for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00 Mil.

Ondine Biomedical Net Issuance of Preferred Stock Historical Data

The historical data trend for Ondine Biomedical's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ondine Biomedical Net Issuance of Preferred Stock Chart

Ondine Biomedical Annual Data
Trend Dec08 Dec09 Dec10 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Issuance of Preferred Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 2.34 - - -

Ondine Biomedical Semi-Annual Data
Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net Issuance of Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Ondine Biomedical Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ondine Biomedical Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Ondine Biomedical's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Ondine Biomedical Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ondine Biomedical Inc (OTCPK:OBIMF) » Definitions » Net Issuance of Preferred Stock
Comparable Companies
LSE:FUM LSE:TRX LSE:SBTX LSE:SAR LSE:OPTI LSE:POLB LSE:AREC AQSE:PBX LSE:IMM LSE:IXI VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
OBI:UK
Address
1100 Melville Street, Suite 888, Vancouver, BC, CAN, V6E4A6
Website
https://www.ondinebio.com
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.